Options for metastatic colorectal cancer beyond the second line of treatment

Digestive and Liver Disease

Volumn 46, Issue 2, 2014, Pages 105-112

  Foubert, Fanny ^a   Matysiak Budnik, Tamara ^a   Touchefeu, Yann ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Intra arterial therapies; Metastatic colorectal cancer; Molecular targeted therapies; Multiline strategy

Indexed keywords

ANGIOGENESIS INHIBITOR; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB;

ANTIANGIOGENIC THERAPY; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CHEMOEMBOLIZATION; CHEMOTHERAPY; DRUG SAFETY; HEPATIC ARTERY INFUSION; HUMAN; LIVER METASTASIS; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; RADIOEMBOLIZATION; REVIEW; TREATMENT OUTCOME; WILD TYPE;

CHEMOTHERAPY; INTRA-ARTERIAL THERAPIES; METASTATIC COLORECTAL CANCER; MOLECULAR TARGETED THERAPIES; MULTILINE STRATEGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PHENYLUREA COMPOUNDS; PYRIDINES;

EID: 84893643857     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.002     Document Type: Review

References (64)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005, 55:74-108.
2. Van Cutsem E., Nordlinger B., Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of Oncology 2010, 21(Suppl. 5):v93-v97.
3. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology 2007, 25:1670-1676.
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350:2335-2342.
5. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Journal of Clinical Oncology 2007, 25:4779-4786.
6. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology 2007, 25:1539-1544.
7. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of Clinical Oncology 2010, 28:4697-4705.
8. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010, 28:4706-4713.
9. Broadbridge V.T., Karapetis C.S., Price T.J. Cetuximab in metastatic colorectal cancer. Expert Review of Anticancer Therapy 2012, 12:555-565.
10. Papa A., Rossi L., Lo Russo G., et al. Emerging role of cetuximab in the treatment of colorectal cancer. Recent Patents on Anti-Cancer Drug Discovery 2012, 7:233-247.
11. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007, 357:2040-2048.
12. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007, 25:1658-1664.
13. Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. Journal of Clinical Oncology 2005, 23:9441-9442.
14. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142.
15. Ducreux M., Malka D., Mendiboure J., et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncology 2011, 12:1032-1044.
16. Tebbutt N.C., Cummins M.M., Sourjina T., et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 2010, 102:475-481.
17. Rothenberg M.L., Oza A.M., Bigelow R.H., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. Journal of Clinical Oncology 2003, 21:2059-2069.
18. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Investigational New Drugs 2000, 18:343-354.
19. Gubanski M., Naucler G., Almerud A., et al. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncologica 2005, 44:236-239.
20. Sawada N., Ishikawa T., Fukase Y., et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clinical Cancer Research 1998, 4:1013-1019.
21. Lim D.H., Park Y.S., Park B.B., et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemotherapy and Pharmacology 2005, 56:10-14.
22. Chong G., Dickson J.L., Cunningham D., et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. British Journal of Cancer 2005, 93:510-514.
23. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. Journal of Clinical Oncology 2006, 24:394-400.
24. de Gramont A., Buyse M., Abrahantes J.C., et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. Journal of Clinical Oncology 2007, 25:3224-3229.
25. de Gramont Lesparre A.H., Chibaudel B., Bourges O., et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. Journal of Clinical Oncology 2009, 27. [abstract].
26. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 2008, 359:1757-1765.
27. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004, 351:337-345.
28. Au H.J., Karapetis C.S., O'Callaghan C.J., et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology 2009, 27:1822-1828.
29. Odom D., Barber B., Bennett L., et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. International Journal of Colorectal Disease 2011, 26:173-181.
30. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006, 66:3992-3995.
31. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27:663-671.
32. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011, 29:2011-2019.
33. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:1626-1634.
34. Siena S., Sartore-Bianchi A., Di Nicolantonio F., et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Journal of the National Cancer Institute 2009, 101:1308-1324.
35. Bossard C., Kury S., Jamet P., et al. Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. Journal of Clinical Pathology 2012, 65:466-469.
36. Italiano A., Hostein I., Soubeyran I., et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Annals of Surgical Oncology 2010, 17:1429-1434.
37. Baldus S.E., Schaefer K.L., Engers R., et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clinical Cancer Research 2010, 16:790-799.
38. Santini D., Vincenzi B., Addeo R., et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Annals of Oncology 2012, 23:2313-2318.
39. Wadlow R.C., Hezel A.F., Abrams T.A., et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 2012, 17:14.
40. Metges J., Raoul J., Achour N., et al. PANERB study: panitumumab after cetuximab-based regimen failure. Journal of Clinical Oncology 2010, 28. [abstract].
41. Yonesaka K., Zejnullahu K., Okamoto I., et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Science Translational Medicine 2011, 3:99ra86.
42. Montagut C., Dalmases A., Bellosillo B., et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine 2012, 18:221-223.
43. Norguet E., Dahan L., Gaudart J., et al. Cetuximab after bevacizumab in metastatic colorectal cancer: is it the best sequence?. Digestive and Liver Disease 2011, 43:917-919.
44. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381:303-312.
45. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008, 26:2013-2019.
46. Bennouna J., Sastre J., Arnold D., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncology 2013, 14:29-37.
47. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Journal of Clinical Oncology 2012, 30:3499-3506.
48. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. Journal of Clinical Oncology 2006, 24:3354-3360.
49. Vincenzi B., Santini D., Russo A., et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 2009, 115:4849-4856.
50. Siu L.L., Shapiro J.D., Jonker D.J., et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. Journal of Clinical Oncology 2012, 30.
51. Wu P.A., Balagula Y., Lacouture M.E., et al. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Current Opinion in Oncology 2011, 23:343-351.
52. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Annals of Surgery 2006, 244:254-259.
53. Riemsma R.P., Bala M.M., Wolff R., et al. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database of Systematic Reviews 2013, 4:CD009498.
54. Hunt T.M., Flowerdew A.D., Birch S.J., et al. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. British Journal of Surgery 1990, 77:779-782.
55. Albert M., Kiefer M.V., Sun W., et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011, 117:343-352.
56. Martin R.C., Joshi J., Robbins K., et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Annals of Surgical Oncology 2011, 18:192-198.
57. Aliberti C., Fiorentini G., Muzzio P.C., et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Research 2011, 31:4581-4587.
58. Arai Y., Takeuchi Y., Inaba Y., et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Techniques in Vascular and Interventional Radiology 2007, 10:30-37.
59. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Annals of Surgical Oncology 2008, 15:219-226.
60. de Baere T., Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdominal Imaging 2011, 36:661-670.
61. Mulcahy M.F., Lewandowski R.J., Ibrahim S.M., et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009, 115:1849-1858.
62. Cianni R., Urigo C., Notarianni E., et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovascular and Interventional Radiology 2009, 32:1179-1186.
63. Hong K., McBride J.D., Georgiades C.S., et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. Journal of Vascular and Interventional Radiology 2009, 20:360-367.
64. Hendlisz A., Van den Eynde M., Peeters M., et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. Journal of Clinical Oncology 2010, 28:3687-3694.